American Association for Cancer Research

SHERPA: Unknown

People

  1. Solit
    Solit
  2. Ladanyi
    Ladanyi
  3. Rosen
    Rosen
  4. Hudis
    Hudis
  5. Scher
    Scher
  6. Baselga
    Baselga
  7. Berger
    Berger
  8. Norton
    Norton
  9. Reis-Filho
    Reis-Filho
  10. Cordon-Cardo
    Cordon-Cardo

Groups

  1. Department of Medicine (2138)
  2. Solid Tumor Oncology Division (1789)
  3. GSK Faculty (1641)
  4. Sloan Kettering Institute Faculty (788)
  5. Sloan Kettering Institute Postdocs (787)
  6. Department of Pathology and Laboratory Medicine (744)
  7. Human Oncology and Pathogenesis Program (687)
  8. Surgery (647)
  9. Breast Medicine Service (611)
  10. Center for Molecular Imaging and Biotechnology (CMIB) (589)
Search Within
Formats
  1. Journal Article (2035)
  2. Meeting Abstract (2011)
  3. Editorial (49)
  4. Review (29)
  5. Conference Paper (14)
  6. Correspondence (6)
  7. Miscellaneous (4)
  8. Guidelines (1)
Groups
  1. Department of Medicine (2138)
  2. Solid Tumor Oncology Division (1789)
  3. GSK Faculty (1641)
  4. Sloan Kettering Institute Faculty (788)
  5. Sloan Kettering Institute Postdocs (787)
  6. Department of Pathology and Laboratory Medicine (744)

More Groups

People
  1. David Solit (176)
  2. Marc Ladanyi (158)
  3. Neal Rosen (142)
  4. Clifford Hudis (141)
  5. Howard Scher (139)
  6. Jose Baselga (138)

More People

Years
  1. 2025 (51)
  2. 2024 (75)
  3. 2023 (79)
  4. 2022 (266)
  5. 2021 (235)
  6. 2020 (272)

More Years

Publications
  1. Cancer Research (2704)
  2. Clinical Cancer Research (1445)

Results (4149)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • IMbassador250: A phase III trial comparing atezolizumab with enzalutamide vs enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Sweeney, C. J.; Gillessen, S.; Rathkopf, D.; Matsubara, N.; Drake, C.; Fizazi, K.; Piulats, J. M.; Wysocki, P. J.; Buchschacher, G. L. Jr; Doss, J.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Chromatin accessibility landscape and transcriptome of castration resistant prostate cancers reveals novel subtypes and diverse master regulators
    Meeting Abstract

    Tang, F.; Wong, C. K.; Cohen, S.; Lee, C.; Liu, M.; Bareja, R.; Eng, K.; Beg, S.; Puca, L.; Sternberg, C.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • A computational model for the PI3K/Akt/mTOR pathway predicts PTEN as a negative feedback loop
    Meeting Abstract

    Vanaja, K.; Mukherjee, R.; Rosen, N.; Levchenko, A.
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors
    Meeting Abstract

    Vasan, N.; Razavi, P.; Johnson, J. L.; Shao, H.; Shah, H.; Antoine, A.; Ladewig, E.; Gorelick, A.; Lin, T. Y.; Toska, E.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Identification of abnormal CSF1 transcripts in tenosynovial giant cell tumors and dose-dependent increase in plasma CSF1 levels in response to pexidartinib treatment
    Meeting Abstract

    Severson, P.; West, B. L.; Tap, W. D.; Wainberg, Z. A.; Tong-Starksen, S.; Hsu, H. H.; Zhang, C.
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Coordinate translational control of the kras signaling pathway
    Meeting Abstract

    Singh, K.; Lin, J.; Lecomte, N.; Mohan, P.; Leach, S. D.; Ouyang, Z.; Wendel, H. G.
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Resistance to anti-HER2 therapy in HER2+ breast cancer is mediated by genomic alterations that switch pathway dependence from PI3K/AKT to RAS/MAPK
    Meeting Abstract

    Smith, A. E.; Chandarlapaty, S.
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Comprehensive pan-cancer analyses of RAS genomic diversity
    Meeting Abstract

    Scharpf, R.; Riely, G.; Awad, M.; Lenoue-Newton, M.; Ricciuti, B.; Rudolph, J.; Raskin, L.; Park, A.; Lee, J.; Lovly, C.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Allosteric inhibition of SHP2 prevents adaptive resistance to MEK inhibition in neurofibromatosis type 1 associated malignant peripheral nerve sheath tumors
    Meeting Abstract

    Sait, S. F.; Tang, K.; Brown, R.; Sun, D.; Xie, X.; Neel, B.; Parada, L.
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Germline mutation prevalence in young adults with cancer
    Meeting Abstract

    Stadler, Z. K.; Maio, A.; Padunan, A.; Kemel, Y.; Salo-Mullen, E.; Sheehan, M.; Belanfanti, K.; Tejada, P. R.; Birsoy, O.; Mandelker, D.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save

    • American Association for Cancer Research – authorized name for: